Roivant Sciences Ltd. (NASDAQ:ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced today the commencement of a proposed underwritten public offering of $150,000,000 of common shares. Roivant expects to grant the underwriter a 30-day option to purchase up to $22.5 million of additional common shares. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Universal Health Services To Rally Around 25%? Here Are 5 Other Price Target Changes For Friday
Credit Suisse raised Universal Health Services, Inc. (NYSE: UHS) price target from $129 to $157. Credit Suisse analyst Jonathan Yong maintained an Outperform rating on the stock. Universal Health fell 2.7% to $126.15 in pre-market trading.
